In part two of this series, Dr. Shuvro Roy talks with Drs. Jiwon Oh and Amit Bar-Or about the latest developments in BTK inhibitors for MS, including safety signals, trial results, and future directions. 

For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting. 

Read more about the Fenebrutinib Trial. 

Disclosures can be found at Neurology.org.